Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Public ClinicalTrials.gov record NCT06948955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Study identification
- NCT ID
- NCT06948955
- Recruitment status
- Available
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Bezuclastinib Drug
- Sunitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- May 7, 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | Available |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Available |
| UCLA Department of Medicine- Hematology/Oncology | Los Angeles | California | 90095 | Available |
| University of Colorado | Aurora | Colorado | 80045 | Available |
| Smillow Cancer Hospital - Yale New Haven Health | New Haven | Connecticut | 06510 | Available |
| Mayo Clinic | Jacksonville | Florida | 32224 | Available |
| Orlando Health | Orlando | Florida | 32806 | Available |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | Available |
| Dana Farber Cancer Institute (DFCI) | Boston | Massachusetts | 02215 | Available |
| Mayo Clinic | Rochester | Minnesota | 55905 | Available |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Available |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | Available |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Available |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | Available |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Available |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Available |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Available |
| Shenandoah Oncology | Winchester | Virginia | 22601 | Available |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06948955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06948955 live on ClinicalTrials.gov.